Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 3,100 shares, a decrease of 27.9% from the October 15th total of 4,300 shares. Based on an average daily volume of 14,400 shares, the short-interest ratio is currently 0.2 days.
Adlai Nortye Stock Down 0.6 %
Shares of NASDAQ:ANL opened at $3.25 on Friday. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48. The stock’s fifty day moving average price is $2.18 and its 200-day moving average price is $4.51.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Adlai Nortye in a research note on Monday, November 11th.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Deciphering Disruption: Inside Cathie Wood’s Latest Plays
- The Role Economic Reports Play in a Successful Investment Strategy
- MarketBeat Week in Review – 11/11 – 11/15
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
